Topoisomerase II as a target for anticancer chemotherapy.

S H Kaufmann; R Hancock

doi:10.18388/abp.1995_4892

Topoisomerase II as a target for anticancer chemotherapy.

S H Kaufmann Division of Oncology Research, Mayo Clinic, Rochester, Minnesota 55905, USA.;
R Hancock

DOI: https://doi.org/10.18388/abp.1995_4892

Abstract

Type II DNA topoisomerases are required for the segregation of genomic DNA at cell division in prokaryotic and eukaryotic cells, and inhibitors of these enzymes are potential cytotoxic agents in both prokaryotes and eukaryotes. The bacterial member of the topoisomerase II family, DNA gyrase, and the chemotherapeutic agents which target it are the subject of a recent review (Maxwell, A. et al., 1993, in Molecular Biology of DNA Topoisomerases, Andoh, T. et al., eds., pp. 21-30, CRC Press, Boca Raton). Here we present an overview of current knowledge of eukaryotic topoisomerase II and the anticancer agents which target this enzyme, focussing predominantly on new observations and recent reports and reviews.

Published

1995-12-31

Issue

Vol. 42 No. 4 (1995)

Section

Articles

Acta Biochimica Polonica is an OpenAccess quarterly and publishes four issues a year. All contents are distributed under the Creative Commons Attribution-ShareAlike 4.0 International (CC BY 4.0) license. Everybody may use the content following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.